PATENT CLAIM ANALYSIS

Application Number: 15893771
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "415000"]

Abstract:
This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.

Claim (Index 7):
A method of treating a disorder selected from muscle wasting associated with chronic obstructive pulmonary disease (COPD), muscle wasting associated with chronic kidney disease (CKD), muscle wasting associated with chronic heart failure (CHF), and urinary incontinence, wherein said method comprises administering a compound according to  claim 1  to a human subject.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 88.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15111068', '13389525', '13941911', '15358458', '14549034']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7515134535132928
- 35 USC 102 Novelty (BERT): 0.5705644115458408
- Combined Prediction Score: 0.7334185493165476
- Mean Citation Score: 238.344134
- Max Citation Score: 441.6624
- Similarity Product: 408.00798466472617

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test